Anti-CD40 antibodies and methods of treating cancer having CD40+ tumor cells
The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with multivalent binding specificity for CD40, which have a potency for dendritic cell activation which is higher than, or is equal to, the potency for B cell activation and wherein the antibody, a...
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | English |
Published |
05.05.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with multivalent binding specificity for CD40, which have a potency for dendritic cell activation which is higher than, or is equal to, the potency for B cell activation and wherein the antibody, antigen-binding fragment, or fusion, variant or derivative thereof has an affinity (KD) for CD40 of less than 1×10−10 M, which have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies. |
---|---|
Bibliography: | Application Number: US201715588919 |